Scarpignato et al. [12] have produced a valuable summary of the current state of knowledge about the GI and CV risks of both nsNSAIDs and COX-2 selective drugs, which will be helpful for clinicians managing patients with osteoarthritis. The gene discussed is PTGS2; the disease is osteoarthritis.